Lidocaine/epinephrine transdermal - Vyteris
Alternative Names: LidoSiteLatest Information Update: 27 Jun 2019
Price :
$50 *
At a glance
- Originator Vyteris
- Class Acetanilides; Analgesics; Catecholamines; Local anaesthetics; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Opioid receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 27 Jun 2019 Chemical structure information added
- 29 May 2013 Vyteris plans to sell transdermal drug delivery patents, subject to approval of US Bankruptcy Court
- 14 Aug 2007 Vyteris launches lidocaine/epinephrine transdermal in the US physician's office market